Celldex Therapeutics’ (CLDX) “Outperform” Rating Reiterated at Wolfe Research

Wolfe Research reiterated their outperform rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note published on Wednesday morning, MarketBeat Ratings reports. They currently have a $51.00 target price on the biopharmaceutical company’s stock.

CLDX has been the subject of a number of other reports. Cantor Fitzgerald reiterated an overweight rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Monday, September 16th. Wells Fargo & Company increased their price target on Celldex Therapeutics from $35.00 to $37.00 and gave the stock an equal weight rating in a report on Monday, August 12th. Stifel Nicolaus started coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They issued a buy rating and a $58.00 price objective on the stock. Finally, HC Wainwright reiterated a buy rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Monday, August 12th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics currently has an average rating of Buy and an average target price of $63.83.

Celldex Therapeutics Trading Up 1.0 %

NASDAQ CLDX opened at $33.20 on Wednesday. Celldex Therapeutics has a 12 month low of $22.11 and a 12 month high of $53.18. The company’s 50 day moving average is $38.35 and its two-hundred day moving average is $38.34. The stock has a market cap of $2.19 billion, a price-to-earnings ratio of -11.65 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The company had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $1.13 million. Sell-side analysts forecast that Celldex Therapeutics will post -2.5 EPS for the current year.

Institutional Trading of Celldex Therapeutics

Large investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in Celldex Therapeutics during the 2nd quarter valued at about $76,000. Headlands Technologies LLC purchased a new position in shares of Celldex Therapeutics in the 1st quarter worth approximately $147,000. CANADA LIFE ASSURANCE Co raised its stake in shares of Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 955 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 1,582 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Celldex Therapeutics in the first quarter worth $283,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.